L’Oréal CEO Hieronimus: Company Expects Business to ‘Slightly Underperform’ Market

The admission of expected underperformance marks a notable shift in tone for a company long positioned as a market beater, and it lands alongside a separate, more constructive claim that weight-loss drugs could lift skincare demand. Those two signals pull in different directions: one speaks to competitive or demand pressure in the core business, the other to a potential new growth vector tied to GLP-1 adoption. What matters is whether the underperformance is framed as cyclical or structural, and whether the skincare tailwind is treated as material or marginal. How management reconciles the two in later disclosures is the open question.